Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Metabolomic adaptations and correlates of survival to immune checkpoint blockade.

Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, Schreiber SL, Stephen Hodi F, Sellers WR, Garraway LA, Clish CB, Choueiri TK, Giannakis M.

Nat Commun. 2019 Sep 25;10(1):4346. doi: 10.1038/s41467-019-12361-9.

2.

Pilot of urgent care center evaluation for acute coronary syndrome.

Radecki RP, Foley KF, Elzinga TS, Horak CP, Gant TE, Papp HM, Morris AJ, Hauser NR, Ertz-Berger BL.

Am J Manag Care. 2019 May 1;25(5):e160-e164.

3.

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S.

Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.

PMID:
30670497
4.

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.

Yusko E, Vignali M, Wilson RK, Mardis ER, Hodi FS, Horak C, Chang H, Woods DM, Robins H, Weber J.

Cancer Immunol Res. 2019 Mar;7(3):458-465. doi: 10.1158/2326-6066.CIR-18-0226. Epub 2019 Jan 11.

PMID:
30635271
5.

Differential activities of the multixenobiotic resistance mechanism in freshwater fishes inhabiting environments of Patagonia Argentina.

Assef YA, Di Prinzio CY, Horak CN.

Comp Biochem Physiol C Toxicol Pharmacol. 2019 Mar;217:32-40. doi: 10.1016/j.cbpc.2018.11.019. Epub 2018 Nov 27.

PMID:
30500451
6.

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.

Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, Weirather JL, Wolchok JD, Postow MA, Pavlick AC, Chesney J, Hodi FS.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaar3342. doi: 10.1126/scitranslmed.aar3342.

PMID:
30021886
7.

Sterility and Safety Validation for Transport Packaging of Organs and Tissues.

Cobos M, Trunzo L, Vogt MV, Romero O, Anessi C, Pachado J, Ciávaro MN, Horak C, Bacqué MC.

Transplant Proc. 2018 Mar;50(2):416-417. doi: 10.1016/j.transproceed.2017.12.050.

PMID:
29579817
8.

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.

Krähenbühl L, Goldinger SM, Mangana J, Kerl K, Chevolet I, Brochez L, Horak C, Levesque M, Dummer R, Cheng PF.

Neoplasia. 2018 Feb;20(2):218-225. doi: 10.1016/j.neo.2017.12.002. Epub 2018 Jan 12.

9.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME, Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG Jr, Choueiri TK, Van Allen EM.

Science. 2018 Feb 16;359(6377):801-806. doi: 10.1126/science.aan5951. Epub 2018 Jan 4.

10.

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M.

J Clin Oncol. 2018 Feb 1;36(4):391-398. doi: 10.1200/JCO.2017.72.2850. Epub 2017 Oct 17.

11.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.

12.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J.

J Clin Oncol. 2018 Feb 1;36(4):383-390. doi: 10.1200/JCO.2016.71.8023. Epub 2017 Jul 3.

PMID:
28671856
13.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA.

Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9.

14.

Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.

Novotny JF Jr, Cogswell J, Inzunza H, Harbison C, Horak C, Averbuch S.

Ann Oncol. 2016 Oct;27(10):1966-9. doi: 10.1093/annonc/mdw288. Epub 2016 Aug 8. No abstract available.

15.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS.

Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270.

16.

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, Melero I, Ascierto PA.

Drugs. 2016 Jun;76(9):925-45. doi: 10.1007/s40265-016-0588-x. Review.

PMID:
27229745
17.

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD.

JAMA Oncol. 2015 Jul;1(4):433-40. doi: 10.1001/jamaoncol.2015.1184.

PMID:
26181250
18.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD.

N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

19.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.

N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

20.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
21.

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.

Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS.

Clin Cancer Res. 2015 Feb 15;21(4):712-20. doi: 10.1158/1078-0432.CCR-14-2468. Epub 2014 Dec 18.

22.

Nivolumab in previously untreated melanoma without BRAF mutation.

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA.

N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.

23.

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA.

J Clin Oncol. 2013 Dec 1;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802. Epub 2013 Oct 21.

24.

Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.

Chang SC, Denne J, Zhao L, Horak C, Green G, Khambata-Ford S, Bray C, Celik I, Van Cutsem E, Harbison C.

Clin Colorectal Cancer. 2013 Sep;12(3):195-203.e2. doi: 10.1016/j.clcc.2013.05.001.

PMID:
23978462
25.

Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.

Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G, Pusztai L.

Oncologist. 2013;18(7):787-94. doi: 10.1634/theoncologist.2013-0075. Epub 2013 Jul 12.

26.

Nivolumab plus ipilimumab in advanced melanoma.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M.

N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

27.

Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.

Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, Chan S, Welcher R, Liu D.

Clin Cancer Res. 2013 Mar 15;19(6):1587-95. doi: 10.1158/1078-0432.CCR-12-1359. Epub 2013 Jan 22.

28.

Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.

Harbison CT, Horak CE, Ledeine JM, Mukhopadhyay P, Malone DP, O'Callaghan C, Jonker DJ, Karapetis CS, Khambata-Ford S, Gustafson N, Trifan OC, Chang SC, Ravetto P, Iv GA.

Arch Pathol Lab Med. 2013 Jun;137(6):820-7. doi: 10.5858/arpa.2012-0367-OA. Epub 2012 Oct 3.

PMID:
23030695
29.

Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.

Marshall JC, Collins JW, Nakayama J, Horak CE, Liewehr DJ, Steinberg SM, Albaugh M, Vidal-Vanaclocha F, Palmieri D, Barbier M, Murone M, Steeg PS.

J Natl Cancer Inst. 2012 Sep 5;104(17):1306-19. doi: 10.1093/jnci/djs319. Epub 2012 Aug 21.

30.

The cetuximab experience: developing predictive biomarkers in oncology.

Harbison CT, Horak CE, Khambata-Ford S.

Per Med. 2011 Mar;8(2):149-159. doi: 10.2217/pme.10.78.

PMID:
29783412
31.

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR.

J Clin Oncol. 2010 Feb 20;28(6):918-27. doi: 10.1200/JCO.2009.25.2890. Epub 2010 Jan 25.

PMID:
20100958
32.

Altered gene and protein expression by Nm23-H1 in metastasis suppression.

Lee JH, Marshall JC, Steeg PS, Horak CE.

Mol Cell Biochem. 2009 Sep;329(1-2):141-8. doi: 10.1007/s11010-009-0124-3. Epub 2009 May 5. Review.

33.

The role of metastasis suppressor genes in metastatic dormancy.

Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS.

APMIS. 2008 Jul-Aug;116(7-8):586-601. doi: 10.1111/j.1600-0463.2008.01213.x. Review.

34.

Clinical-translational approaches to the Nm23-H1 metastasis suppressor.

Steeg PS, Horak CE, Miller KD.

Clin Cancer Res. 2008 Aug 15;14(16):5006-12. doi: 10.1158/1078-0432.CCR-08-0238. Review.

35.

Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility.

Lee JH, Horak CE, Khanna C, Meng Z, Yu LR, Veenstra TD, Steeg PS.

Cancer Res. 2008 Feb 1;68(3):639-44. doi: 10.1158/0008-5472.CAN-07-2632.

36.

Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.

Horak CE, Mendoza A, Vega-Valle E, Albaugh M, Graff-Cherry C, McDermott WG, Hua E, Merino MJ, Steinberg SM, Khanna C, Steeg PS.

Cancer Res. 2007 Dec 15;67(24):11751-9.

37.

Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth.

McDermott WG, Boissan M, Lacombe ML, Steeg PS, Horak CE.

Clin Exp Metastasis. 2008;25(2):131-8. Epub 2007 Dec 5.

PMID:
18058029
38.

Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.

Horak CE, Lee JH, Elkahloun AG, Boissan M, Dumont S, Maga TK, Arnaud-Dabernat S, Palmieri D, Stetler-Stevenson WG, Lacombe ML, Meltzer PS, Steeg PS.

Cancer Res. 2007 Aug 1;67(15):7238-46.

39.

Translational approaches using metastasis suppressor genes.

Palmieri D, Horak CE, Lee JH, Halverson DO, Steeg PS.

J Bioenerg Biomembr. 2006 Aug;38(3-4):151-61. Review.

PMID:
16944301
40.

c-Met ectodomain shedding rate correlates with malignant potential.

Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4154-62.

41.

Metastasis gets site specific.

Horak CE, Steeg PS.

Cancer Cell. 2005 Aug;8(2):93-5.

42.

Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.

Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, Figg WD, Hollingshead M, Hursting S, Berrigan D, Steinberg SM, Merino MJ, Steeg PS.

J Natl Cancer Inst. 2005 May 4;97(9):632-42.

PMID:
15870434
43.

ExpressYourself: A modular platform for processing and visualizing microarray data.

Luscombe NM, Royce TE, Bertone P, Echols N, Horak CE, Chang JT, Snyder M, Gerstein M.

Nucleic Acids Res. 2003 Jul 1;31(13):3477-82.

44.

Complex transcriptional circuitry at the G1/S transition in Saccharomyces cerevisiae.

Horak CE, Luscombe NM, Qian J, Bertone P, Piccirrillo S, Gerstein M, Snyder M.

Genes Dev. 2002 Dec 1;16(23):3017-33.

45.

Global analysis of gene expression in yeast.

Horak CE, Snyder M.

Funct Integr Genomics. 2002 Sep;2(4-5):171-80. Epub 2002 Jul 10. Review.

PMID:
12192590
46.

ChIP-chip: a genomic approach for identifying transcription factor binding sites.

Horak CE, Snyder M.

Methods Enzymol. 2002;350:469-83. No abstract available.

PMID:
12073330
47.

GATA-1 binding sites mapped in the beta-globin locus by using mammalian chIp-chip analysis.

Horak CE, Mahajan MC, Luscombe NM, Gerstein M, Weissman SM, Snyder M.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2924-9. Epub 2002 Feb 26.

49.

Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF.

Iyer VR, Horak CE, Scafe CS, Botstein D, Snyder M, Brown PO.

Nature. 2001 Jan 25;409(6819):533-8.

PMID:
11206552
50.

House-fly cytochrome P450 CYP6D1: 5' flanking sequences and comparison of alleles.

Scott JG, Liu N, Wen Z, Smith FF, Kasai S, Horak CE.

Gene. 1999 Jan 21;226(2):347-53.

PMID:
9931509

Supplemental Content

Support Center